Home > Back to Publisher > Report Information

Effective Deal Making in Drug Delivery

PharmaVentures Ltd.
February 1, 2009
SKU: PHV2122377

Abstract Table of Contents Related Reports

Countries covered: United States

"Looming patent expiry a major force in driving valuation"

Drugs with annual sales totalling over US$86 B in 2007 are due to go off patent by 2012. Therefore, the application of novel drug delivery technologies to such existing therapeutics is an attractive means of prolonging the commerical viability of marketed drugs.

Technologies are more difficult to value than products in clinical development because the technical risks or success rates are less well documented, and costs and timescales are less predictable.

It is very important to benchmark when valuing technologies and to have a thorough understanding of the risks and rewards.

This new PharmaDeals® Report, covers the range of strategies and offerings available to the deal maker, and is vital for understanding growth and survival in volatile markets.

1 Introduction

2 Market Overview

2.1 Types of Drug Delivery

2.2 Development of the Drug Delivery Market

2.3 The Current and Evolving Market

2.4 Future Market Challenges

2.5 Drug Delivery Companies

2.5.1 Principal Players in Drug Delivery

2.5.2 The Changing Landscape: M&A Activity

2.5.3 The True Scope of the Drug Delivery

Sector

3 Key Drivers in Drug Delivery

3.1 Improving the Therapeutic Index

3.2 Patient Compliance

3.3 Patent Prolongation

3.4 Life Cycle Management

4 Commercialisation Strategies

4.1 Introduction

4.2 Returns to Innovation

4.3 Drug Delivery Product Offerings

4.4 Exploitation Strategies

4.5 Business Models

4.6 Product, Strategy and Business Models for Drug Delivery Technology

4.7 Applicability to Segments of the Pharmaceutical Product Life Cycle

4.8 Assessment of Attractiveness of Each Option

4.8.1 Divestment to a Service-Based Company

4.8.2 Licensing to Pharmaceutical Companies

4.8.3 Sales of Devices

4.8.4 Service Offering

4.8.5 Development of Drugs in Collaboration with other Companies

4.8.6 In-House Drug Development

4.9 Compatibility of Product Offerings

4.10 Conclusion

5 Alliances in Drug Delivery

5.1 Drug Delivery Deals Database

5.2 Drug Delivery Deal Activity

5.3 Financial Analysis of Drug Delivery Deals

6 Major Pharmaceutical Company Drug

Delivery Deal Activity

6.1 Johnson & Johnson

6.2 Pfi zer

6.3 GlaxoSmithKline (GSK)

6.4 Novartis

6.5 Sanofi -aventis

6.6 Roche

6.7 AstraZeneca

6.8 Merck & Co

6.9 Abbott Laboratories

6.10 Wyeth

7 Valuation Methods

7.1 Integrated Benchmarking and ENPV Calculation

7.2 Other Methods

7.3 Benchmarking

7.3.1 Feasibility Search

7.3.2 Information Gathering and Analysis

7.3.3 Approximate Valuation

7.3.4 Refi nement of Valuation

7.4 Expected Net Present Value

7.5 Agreement Structure

7.5.1 Value Sharing

7.5.2 Risk Sharing

7.6 Valuation of Drug Delivery Systems

7.6.1 Enabling Technology

7.6.2 Enhancing Technology

8 Drug Delivery Alliance Development

Process

8.1 Needs Identifi cation

8.1.1 Driving Factors

8.1.1.1 Market Drivers

8.1.1.2 Technology Drivers

8.1.2 Tools Needs Identifi cation

8.1.2.1 Portfolio Analysis

8.1.2.2 Value Chain Analysis

8.2 Identifying Opportunities and Partners

8.3 Development of Commercial Relationships

9 Drug Delivery Agreements

Tables

1 Typical maximum doses per administration

2 Marketed recombinant biopharmaceuticals

among the top 200 selling prescription drugs

3 Publicly quoted specialty pharmaceutical

companies that focus on drug delivery

4 Elan’s partnering activity

5 Major patent expirations, 2008-2012

6 Strategies for the exploitation of innovation

7 Business models

8 Generic strategies for commercialisation

9 Product offerings and target segments

10 Compatibility of product offerings

11 Number of drug delivery deals by therapeutic

area, 1997-October 2008

12 Number of drug delivery deals by product type,

1997-October 2008

13 Average total deal values for drug delivery deals,

1997-October 2008

14 Average upfront payments for drug delivery deals,

1997-October 2008

15 Average milestone payments for drug delivery

deals, 1997-October 2008

16 Average equity investment payments for drug

delivery deals, 1997-October 2008

17 Top ten pharmaceutical companies by 2007

worldwide healthcare revenue

18 Johnson & Johnson drug delivery deals

19 Alza drug delivery deals (part of Johnson &

Johnson)

20 Pfi zer drug delivery deals

21 Pharmacia drug delivery deals

22 GlaxoSmithKline drug delivery deals

23 Novartis drug delivery deals

24 Sanofi -Aventis drug delivery deals

25 Roche drug delivery deals

26 AstraZeneca drug delivery deals

27 Abbott drug delivery deals

28 Merck & Co. drug delivery deals

29 Wyeth drug delivery deals

30 Benchmarking methodology overview

31 Sources of information

32 Cumulative probabilities

33 Example ENPV calculation

34 Pharmaceutical industry event calendars

35 Key factors leading to successful alliancesbetween companies

36 Drug delivery agreements linked to

Figures

1 Pharmaceutical company R&D drug delivery

projects by route of delivery

2 Drug delivery mergers and acquisitions,

1997-2008

3 Effect of controlled release formulations

4 Doses of chemotherapeutic agent required to

achieve maximum effect

5 Estimated value in 2008 worldwide sales of the

top 200 prescription drugs by year of US

patent expiry

6 Life cycle management

7 All deal activity, 1997-2008

8 Drug delivery deal activity, 1997-2008

9 All deals according to deal type, 1997-2008

10 Drug delivery deals according to deal type,

1997-2008

11 Number of drug delivery deals by

therapeutic area, 1997-2008

12 Number of drug delivery deals by product type,

1997-2008

13 Percentage of all deals with some fi nancial

information, 1997-2008

14 Percentage of drug delivery deals with some

fi nancial information, 1997-2008

15 Integrated valuation methods

16 Ideal benchmarking deal cluster

17 Example pharmaceutical deal force fi eld

18 Attrition by therapeutic area

19 Success rates for life cycle

management projects

20 Pharmaceutical product decision tree

21 Enhanced revenues due to

drug delivery system

22 Enhancement of patent life

23 Drug delivery alliance development process

More United States Drug Delivery Reports

Freedonia Focus on Implantable Medical Devices: United States by Freedonia Focus
This report discusses US demand for implantable medical devices for the years 2005 and 2010, with forecasts for 2015. Topics covered include market size, product ...

Implantable Medical Devices by Freedonia Group Inc
US demand to increase 7.7% annually through 2015 US demand for implantable medical devices will increase 7.7 percent annually to $52 billion in 2015. These ...

Freedonia Focus on Drug Delivery Products: United States by Freedonia Focus
This report discusses US drug delivery products demand for the years 2005 and 2010, with forecasts for 2015. Topics covered include market size, product and ...

Drug Delivery Systems by Freedonia Group Inc
US demand to rise 7.2% annually through 2015 US demand for drug delivery products is forecast to expand 7.2 percent annually to $133 billion in ...

US Market for Implantable Medical Devices by Taiyou Research
It is expected that the demand for implantable medical devices in the United States will increase by nearly 8.5 percent by 2015. Although weakened in ...

See all reports like this >>

More United States Reports

e-Discovery Software Publishing in the US - Industry Market Research Report by IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...

See all reports like this >>

Effective Deal Making in Drug Delivery

Share this report

Other tasks

Research Assistance

Related Markets

Drug Delivery Reports

Free Alert Me service